RT Journal Article SR Electronic T1 Perspectives in immunotherapy: meeting report from the “Immunotherapy Bridge”, Napoli, December 5th 2015 JF Journal for ImmunoTherapy of Cancer JO J Immunother Cancer FD BMJ Publishing Group Ltd SP 62 DO 10.1186/s40425-016-0168-3 VO 4 IS 1 A1 Paolo A. Ascierto A1 Maria Libera Ascierto A1 Silvia Formenti A1 Sacha Gnjatic A1 Hans Hammers A1 Vera Hirsh A1 Rolf Kiessling A1 Ignacio Melero A1 Rita Nanda A1 Graham Pawelec A1 Sandro Pignata A1 Pedro Romero A1 Daniel E. Speiser A1 Bernard A. Fox A1 Francesco M. Marincola YR 2016 UL http://jitc.bmj.com/content/4/1/62.abstract AB Harnessing the immune system and preventing immune escape, the immunotherapy of cancer provides great potential for clinical application, in broad patient populations, achieving both conventional and unconventional clinical responses. After the substantial advances in melanoma, the focus of cancer immunotherapy has expanded to include many other cancers. Targeting immune checkpoints and further mechanisms used by tumors to avoid anticancer immunity, different approaches are under evaluation, including combination therapies.The first Immunotherapy Bridge meeting focused on various cancer types including melanoma, non-small cell lung cancer, renal cell, breast and ovarian carcinoma, and discussed mechanisms of action of single agents and combination strategies, and the prediction of clinical responses.Abbreviations:ADCCAntibody-dependent cell- mediated cytotoxicityAEAdverse eventASCTAuthologous stem cell transplantationBRCABreast related cancer antigensCCLChemokine ligandCEACarcino-embryonic antigenCSF-R1Colony stimulating factor 1 receptorCTCancer testisCTLCytotoxic T lymphocyteCTLA-4Cytotoxic T lymphocyte antigen 4DCDendritic cellELISAEnzyme-linked immunosorbent assayELISPOTEnzyme-linked immunospotEREstrogen receptorFDAFood and Drug AdministrationFOXO1Forkhead box protein O1GM-CSFGranulocyte-macrophage colony-stimulating factorHCCHepatocellular carcinomaHER-2Human epidermal growth factor receptor 2HLAHuman leucocyte antigensICDImmunogenic cell deathIFAIncomplete Freund’s AdjuvantIFNγInterferon gammairPFSImmune-related progression-free survivalLAG-3Lymphocyte-activation gene 3MAGE-A3Melanoma AntiGen Encoding-antigen 3MDSCMyeloid-derived suppressor cellmTORMammalian target of rapamycinNKNatural killerNKTNatural killer T cellsNSCLCNon-small-cell lung cancerOCOvarian cancerORROverall response rateOSOverall survivalPBMCPeripheral blood mononuclear cellPCRPolymerase chain reactionPD-1Programmed cell death protein 1PD-L1Programmed death ligand 1PFSProgression-free survivalRCCRenal cell cancerRTRadiotherapysdRNASeed region ribonucleic acidTAATumor-associated antigenTGFTransforming growth factorTILTumor-infiltrating lymphocyteTLRToll-like receptorTMETumor microenvironmentTNBCTriple-negative breast cancerT-regRegulatory T cellsT-VECTalimogene laherparepvecVEGFVascular endothelial growth factor